AstraZeneca (AZN) 주식 개요
바이오 제약 회사인 AstraZeneca PLC는 처방 의약품의 발견, 개발, 제조 및 상용화에 주력하는 회사입니다. 자세히 보기
AZN Community Fair Values
Create NarrativeSee what 299 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AstraZeneca PLC 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | UK£125.94 |
| 52주 최고가 | UK£157.32 |
| 52주 최저가 | UK£98.92 |
| 베타 | 0.22 |
| 1개월 변동 | -6.52% |
| 3개월 변동 | -16.70% |
| 1년 변동 | 22.34% |
| 3년 변동 | 16.94% |
| 5년 변동 | 48.51% |
| IPO 이후 변동 | 1,796.69% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jul 16
AZN: Trial Setbacks And Oncology Deals Will Shape Medium Term Credibility
AstraZeneca's updated analyst price targets show a modest reset lower, with recent research pointing to greater uncertainty around medium term revenue catalysts and mixed trial outcomes, even as some analysts continue to highlight areas of support within the broader pipeline and existing portfolio. Analyst Commentary Recent research on AstraZeneca highlights a mix of caution and support, with several firms revisiting their models after the CARDIO TTRansform outcome and reassessing how much risk investors are taking on around the medium term growth story.
내러티브 업데이트 • Jul 02
AZN: Oncology Approvals And Pipeline Execution Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets by about £10, citing updated assumptions that include a modestly lower fair value estimate, a slightly higher discount rate, and adjusted expectations for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on AstraZeneca points to a mix of product specific updates and valuation work, with several bullish analysts adjusting their views as new information filters through on the pipeline and regulatory outcomes.Recent updates
내러티브 업데이트 • Jul 16
AZN: Trial Setbacks And Oncology Deals Will Shape Medium Term Credibility
AstraZeneca's updated analyst price targets show a modest reset lower, with recent research pointing to greater uncertainty around medium term revenue catalysts and mixed trial outcomes, even as some analysts continue to highlight areas of support within the broader pipeline and existing portfolio. Analyst Commentary Recent research on AstraZeneca highlights a mix of caution and support, with several firms revisiting their models after the CARDIO TTRansform outcome and reassessing how much risk investors are taking on around the medium term growth story.내러티브 업데이트 • Jul 02
AZN: Oncology Approvals And Pipeline Execution Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets by about £10, citing updated assumptions that include a modestly lower fair value estimate, a slightly higher discount rate, and adjusted expectations for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Recent Street research on AstraZeneca points to a mix of product specific updates and valuation work, with several bullish analysts adjusting their views as new information filters through on the pipeline and regulatory outcomes.분석 기사 • Jun 19
AstraZeneca (LSE:AZN) Stock Could Be 20.2% Below Fair Value After Recent Pullback
AstraZeneca (LSE:AZN) is back in focus after recent share price pressure, with the stock down about 5% over the past month and past 3 months. This has prompted investors to reassess its long term profile. See our latest analysis for AstraZeneca. Despite the recent share price decline, with the stock down 5.3% on a 90 day share price return basis and currently trading at £131.54, AstraZeneca still shows a 73.7% total shareholder return over five years. This suggests long term holders have seen...
내러티브 업데이트 • Jun 18
AZN: New Approvals And AI Use Will Support Future Repricing
The latest narrative update on AstraZeneca reflects a modest trimming of the analyst fair value estimate to £164.85, as analysts factor in updated revenue growth and profit margin assumptions following recent price target increases and ongoing commentary around the company’s drug pipeline and regulatory outcomes. Analyst Commentary Recent Street research around AstraZeneca centers on how regulators and pricing decisions may affect the company’s growth options, as well as how advisory outcomes could influence execution risk in parts of its pipeline.내러티브 업데이트 • Jun 03
AZN: Recent Drug Approvals And Key Readouts Will Support Bullish Repricing
Analysts have lifted their AstraZeneca price targets by up to £1,000 per share, pointing to updated valuation work that reflects Baxfendy's FDA approval, recent price target revisions from several banks, and slight tweaks to fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. Analyst Commentary Recent research around AstraZeneca clusters into two camps, with some analysts leaning more optimistic after Baxfendy's approval and a series of price target moves, while others highlight execution and regulatory questions that could affect how those targets are met.내러티브 업데이트 • Apr 29
AZN: Pipeline Readouts And 2H26 Catalyst Path Will Drive Bullish Repricing
AstraZeneca's analyst price targets have been raised in recent research, with moves such as Guggenheim's lift to £160.00 and Citi's and Morgan Stanley's increases in their London based targets, as analysts point to refreshed models, updated earnings views and a more constructive stance on the pipeline. Analyst Commentary Recent research around AstraZeneca centres on refreshed valuation work, updated earnings paths and how the pipeline feeds into longer term growth expectations.내러티브 업데이트 • Apr 15
AZN: Updated Oncology Pipeline Outlook Will Support Multi Year Re Rating
Analysts have lifted their AstraZeneca price targets, with several recent moves in the £500 to £1,000 range. They cite stronger confidence in the earnings outlook and pipeline after updated models and conference follow ups.내러티브 업데이트 • Apr 01
AZN: 1H26 Trial Cluster Will Test Sustained Premium Earnings Expectations
AstraZeneca's updated analyst price target reflects a modest uplift, with the fair value estimate moving from £117.29 to £124.85 as analysts factor in refreshed models after recent results, a higher assumed future P/E of about 25x, and ongoing optimism around the earnings pipeline highlighted in recent research. Analyst Commentary Recent research on AstraZeneca has included a series of price target revisions, with several large banks updating their models following full year results and subsequent investor events.내러티브 업데이트 • Mar 18
AZN: Oncology Pipeline And Breast Cancer Trial Readouts Will Support Re Rating
Analysts have lifted AstraZeneca's fair value estimate from £182.81 to £205.97 and raised several price targets, citing updated models, a higher assumed profit margin and a more constructive view on the earnings pipeline. Analyst Commentary Recent Street research points to a cluster of upbeat views on AstraZeneca, with several bullish analysts revisiting their models and adjusting price targets after fresh company updates and sector readthroughs.내러티브 업데이트 • Mar 03
AZN: Oncology Pipeline And 2H26 Catalysts Will Shape Balanced Long-Term Outlook
The updated analyst price target for AstraZeneca increases to £162.67 from £152.79. This reflects broader Street research that highlights stronger earnings potential and a more constructive view on the company’s pipeline and long term growth drivers.내러티브 업데이트 • Feb 17
AZN: Elevated Margin Assumptions Will Face Pressure From Pipeline And Competition Risks
Narrative Update: AstraZeneca Analyst Price Target Shift Analysts have raised their fair value estimate for AstraZeneca from £108.53 to £117.29, citing updated assumptions for revenue growth, profit margins and a lower future P/E multiple, supported by recent price target increases and fresh bullish coverage across several banks. Analyst Commentary Recent Street research on AstraZeneca has leaned positive, with several banks adjusting fair value estimates and starting coverage with supportive views.내러티브 업데이트 • Feb 03
AZN: Oncology Pipeline And Manufacturing Investments Will Shape Balanced Long-Term Outlook
Analysts have lifted their AstraZeneca fair value estimate to £152.79 from £150.26, reflecting higher price targets from several firms and updated views on the company’s revenue growth, profit margins and future P/E assumptions. Analyst Commentary Recent Street research on AstraZeneca has been active, with several bullish analysts lifting price targets and initiating positive coverage.내러티브 업데이트 • Jan 20
AZN: Oncology Pipeline And 2030 Sales Ambition Will Support Re Rating
Narrative Update The analyst price target for AstraZeneca has been nudged higher to reflect a fair value estimate of £182.81 per share, with analysts pointing to supportive Street research that includes recent target upgrades from Deutsche Bank and Barclays, as well as constructive commentary on oncology and the broader biopharma pipeline. Analyst Commentary Recent Street research reflects a cluster of bullish analysts lifting price targets on AstraZeneca, with several pointing to oncology and the broader biopharma pipeline as key parts of their constructive view.내러티브 업데이트 • Jan 06
AZN: Oncology And Biopharma Execution Will Offset Patent Pressure Concerns
AstraZeneca's implied fair value has shifted from £173.72 to £182.32 as analysts weigh stronger confidence in oncology and broader biopharma sales potential against concerns about approaching patent pressures and a less certain pipeline in breast cancer. Analyst Commentary Recent research shows a split in views, but bullish analysts see room for AstraZeneca's valuation to reflect stronger confidence in oncology and biopharma execution, even as others flag upcoming patent risks and breast cancer pipeline uncertainty.내러티브 업데이트 • Dec 14
AZN: Oncology Execution And US Manufacturing Expansion Will Drive Long-Term Upside Potential
Analysts have nudged their fair value estimate for AstraZeneca higher to approximately $150.26 from about $146.44, reflecting confidence that the company can deliver on its long term, oncology driven growth ambitions despite mixed views on patent risk and pipeline momentum. Analyst Commentary Recent Street research highlights a sharp divergence in views on AstraZeneca, with some bullish analysts emphasizing the durability of its oncology growth engine and others warning that the valuation already discounts too optimistic a pipeline and patent outcome.내러티브 업데이트 • Nov 28
AZN: Oncology Pipeline Execution And Patent Expiry Risks Will Define Long-Term Prospects
AstraZeneca's analyst price target was revised slightly higher from £145.43 to £146.44, as analysts cite optimism around the company's oncology franchises and biopharma pipeline. Some remain cautious given upcoming patent pressures and mixed views on pipeline outlook.내러티브 업데이트 • Nov 14
AZN: Oncology Pipeline Momentum And Patent Pressures Will Shape Outlook Amid Policy Changes
AstraZeneca's analyst price target has inched higher from $144.38 to $145.43, as analysts cite ongoing strength in its oncology franchises and biopharma pipeline, along with improved margin expectations. Analyst Commentary Recent Street research on AstraZeneca reflects a wide range of perspectives on the company's outlook, with both bullish and bearish analysts voicing key points of emphasis around valuation, pipeline potential, and execution risks.분석 기사 • Nov 13
AstraZeneca's (LON:AZN) Performance Is Even Better Than Its Earnings Suggest
AstraZeneca PLC's ( LON:AZN ) strong earnings report was rewarded with a positive stock price move. We have done some...내러티브 업데이트 • Oct 31
AZN: In-Market Oncology And U.S. Drug Pricing Will Shape Long-Term Performance
AstraZeneca's analyst-derived fair value has been raised to $144.38 per share from $140.96. This reflects modest increases in pipeline confidence and anticipated revenue growth, as noted by analysts in recent research updates.주주 수익률
| AZN | GB Pharmaceuticals | GB 시장 | |
|---|---|---|---|
| 7D | -1.9% | -3.3% | 1.1% |
| 1Y | 22.3% | 22.3% | 17.3% |
수익률 대 산업: AZN은 지난 1년 동안 22.3%의 수익을 기록한 UK Pharmaceuticals 산업과 동일한 성과를 보였습니다.
수익률 대 시장: AZN은 지난 1년 동안 17.3%를 기록한 UK 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| AZN volatility | |
|---|---|
| AZN Average Weekly Movement | 4.1% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.7% |
안정적인 주가: AZN는 지난 3개월 동안 UK 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: AZN의 주간 변동성(4%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1992 | 96,100 | Pascal Claude Soriot | www.astrazeneca.com |
아스트라제네카 PLC는 바이오 제약 회사로 처방 의약품의 발견, 개발, 제조 및 상용화에 주력하고 있습니다. 이 회사는 임주도, 데이터웨이, 이레사, 타그리소, 임핀지, 린파자, 칼퀀스, 인핸서투, 오르파티스, 트루캡, 졸라덱스, 파슬로덱스, 크레스토, 안덱사, 옹리자, 심린, 시그듀오 XR, 아타칸드 등을 제공합니다, 아타칸드 HCT, 아타칸드 플러스, 파시가/포르시가, 플렌딜, 모딥, 스플렌딜, 무노발, 플로딜, 테노민, 테노민, 프레노민, 아테놀, 제스트릴, 브릴린타/브리니크, 콤보글리제, 큐턴, 와이나, 바이에타, 로켈마, 셀로켄 ZOK, 토프롤-XL, 베타록 ZOK, 시그듀오, 아콜레이트, 아콜레이트, 밴티콘, 브리카닐 레스퓰, 에클리라 제네에어/투도르자/브레타리, 풀미코르 터부헬러, 심비코르 터부헬러, 에어수프라, 에어스프라, 브리카닐 터부헬러, 파센라, 라이노코트, 테즈스파이어, 베베스피 에어로스피어, 달리레스프/닥사스, 옥시스 터부헬러, 사프넬로, 브레즈트리 에어로스피어, 듀아클리르 제뉴에어, 풀미코트 레스퓰, 심비코트 pMDI를 공급합니다. 또한 베이포르투스, 카비갈레, 에부셰드, 플루엔즈/플루미스트, 시나기스, 카누마, 울토미리스, 코셀루고, 보이데야, 솔리리스, 스트렌식, 넥시움 등의 의약품을 공급합니다.
AstraZeneca PLC 기초 지표 요약
| AZN 기초 통계 | |
|---|---|
| 시가총액 | UK£195.34b |
| 순이익 (TTM) | UK£7.72b |
| 매출 (TTM) | UK£44.91b |
25.3x
주가수익비율(P/E)4.3x
주가매출비율(P/S)AZN는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| AZN 손익계산서 (TTM) | |
|---|---|
| 매출 | US$60.44b |
| 매출원가 | US$11.18b |
| 총이익 | US$49.26b |
| 기타 비용 | US$38.87b |
| 순이익 | US$10.39b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
Jul 27, 2026
| 주당순이익(EPS) | 6.70 |
| 총이익률 | 81.51% |
| 순이익률 | 17.19% |
| 부채/자본 비율 | 67.8% |
AZN의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기배당
1.8%
현재 배당 수익률48%
배당 성향기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/07/17 00:01 |
| 종가 | 2026/07/17 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
AstraZeneca PLC는 56명의 분석가가 다루고 있습니다. 이 중 24명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| null null | ABG Sundal Collier |
| John Eade | Argus Research Company |
| Odile Rundquist | Baader Helvea Equity Research |